Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Findings from the Phase II single center study published today in JAMA Oncology.
The trial enrolled 42 patients across three cohorts to evaluate mutation-matched targeted therapy and...
